RecruitingPhase 4NCT07152392
Rare condition
Growth delay due to insulin-like growth factor I resistance
4
studies recruiting now
as of 7 Sept 2026
70
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
3 Sept 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 4NCT07152340
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
RecruitingPhase 4NCT07152366
Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.
RecruitingPhase 2 / Phase 3NCT06112340
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Showing the 4 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Growth delay due to insulin-like growth factor I resistance studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Growth delay due to insulin-like growth factor I resistance study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Growth delay due to insulin-like growth factor I resistance
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (IGF1R).
Treatments being studied
3 approved treatments and 4 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Mecasermin (Bio-fd&c igf1)Approved: Lonapegsomatropin (Skytrofa)Approved: Somatropin (Genotropin)
Phase 3Albusomatropin
Phase 3Somapacitan (Sogroya)
Phase 2/3Testosterone (Androderm)
Phase 2/3Letrozole (Femara)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).